

GAU ~~1801~~ 1652
Patent Docket P1129#5/IDS
5-30-98
KD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



<p>Inter Office Application of Ashkenazi et al.</p> <p>Serial No.: 08/918,874</p> <p>Filed: 26 August 1997</p> <p>For: RTD RECEPTOR</p>	<p>Group Art Unit: 1801</p> <p>Examiner: To Be Assigned</p> <hr/> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>May 20, 1998 <i>Janet Tse</i> Janet Tse</p>
---	--

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d) ☐ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$240) set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$240.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

- (e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$130) set forth in 37 CFR §1.17(i) **and** a statement as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$130.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (d) or (e) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.] The undersigned states that:

- ☐ Each item of information contained in the information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A list of the patent(s) or publication(s) is set forth on the attached Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith:

☒ each ☐ none ☐ only those listed below; except those items marked with an asterisk (*).

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention," MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may

be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

GENENTECH, INC.

Date: May 20, 1998

By:



Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

MAY 22 1998
(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	1 3,691,016	12.09.72	Patel, R.			
	2 3,969,287	13.07.76	Jaworek et al.			
	3 4,179,337	18.12.79	Davis et al.			
	4 4,195,128	25.03.80	Hildebrand et al.			
	5 4,229,537	21.10.80	Hodgins et al.			
	6 4,247,642	27.01.81	Hirohara et al.			
	7 4,301,144	17.11.81	Iwashita et al.			
	8 4,330,440	18.05.82	Ayers et al.			
	9 4,342,566	03.08.82	Theofilopoulos et al.			
	10 4,399,216	16.08.83	Axel et al.			
	11 4,419,446	06.12.83	Howley et al.			
	12 4,496,689	29.01.85	Mitra, G.			
	13 4,601,978	22.07.86	Karin, M.			
	14 4,640,835	03.02.87	Shimizu et al.			
	15 4,670,417	02.06.87	Iwasaki et al.			
	16 4,676,980	30.06.87	Segal et al.			
	17 4,736,866	12.04.88	Leder et al.			
	18 4,791,192	13.12.88	Nakagawa et al.			
	19 4,816,567	28.03.89	Cabilly et al.			
	20 4,870,009	26.09.89	Evans et al.			
	21 4,965,199	23.10.90	Capon et al.			
	22 5,010,182	23.04.91	Brake et al.			
	23 5,364,934	15.11.94	Drayna et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	24 003,089	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)			
	25 036,776	30.09.81	EPO			
	26 073,657	09.03.83	EPO			
	27 117,058	29.08.84	EPO			
	28 117,060	29.08.84	EPO			
	29 125,023 A1	14.11.84	EPO			
	30 321,196	21.06.89	EPO			
	31 362,179	04.04.90	EPO			
	32 417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)			
	33 266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)			

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use separate sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	34 WO 87/05330	11.09.87	PCT			
	35 WO 89/02922	06.04.89	PCT			
	36 WO 89/05859	29.06.89	PCT			
	37 WO 90/13646	15.11.90	PCT			
	38 WO 91/00358	10.01.91	PCT			
	39 WO 91/00360	10.01.91	PCT			
	40 WO 92/20373	26.11.92	PCT			
	41 WO 93/08829	13.05.93	PCT			
	42 WO 94/04679	03.03.94	PCT			
	43 WO 94/04690	03.03.94	PCT			
	44 WO 94/29348	22.12.94	PCT			
	45 2,211,504	05.07.89	UNITED KINGDOM			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 46	Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed., IRL Press (1991)
* 47	Tissue Culture, Kruse and Patterson, eds., Academic Press (1973)
48	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for μ , α , $\gamma 1$, $\gamma 2a$, and $\gamma 3$ chains" <u>Biochemistry</u> 19:2711-2719 (1980)
49	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
50	Aplin et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-305 (1981)
51	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoconjugate" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
52	Baldwin, "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-681 (1996)
53	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" <u>Cell</u> 33:729-740 (July 1983)
54	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
55	Barr et al., "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
56	Bianchi et al., "Transformation of the yeast <i>Kluyveromyces fragilis</i> by New Vectors Derived from the 1.6 μ m Circular Plasmid pKD1" <u>Curr. Genet.</u> 12:185-192 (1987)
57	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

MAY 2 (Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 58 | Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991) |
| 59 | Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996) |
| 60 | Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995) |
| 61 | Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984) |
| 62 | Bradley,, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987) |
| 63 | Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990) |
| 64 | Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987) |
| 65 | Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (Nov 29, 1996) |
| 66 | Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" <u>Year in Immunology</u> 7:33-40 (1993) |
| 67 | Byrn et al., "Biological Properties of a CD4 Immunoadhesin" <u>Nature</u> 344:667-670 (April 12, 1990) |
| 68 | Canaani et al., "Regulated Expression of Human Interferon β 1 Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982) |
| 69 | Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989) |
| 70 | Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992) |
| 71 | Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985) |
| 72 | Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978) |
| 73 | Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996) |
| 74 | Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995) |
| 75 | Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996) |
| 76 | Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997) |
| 77 | Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

78	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
79	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)
80	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)
81	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)
82	Creighton,, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)
83	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)
84	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)
85	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)
86	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (Oct 6, 1997)
87	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)
88	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)
89	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)
90	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)
91	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
92	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
93	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)
94	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)
95	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)
96	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <u>Nature</u> 273:113-120 (May 11, 1978)
97	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces</i> Yeasts" <u>Bio/Technology</u> 9:968-975 (1991)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1129	Serial No. 08/918,874
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 26 Aug 1997	Group 1801
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
		Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)			
99		Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)			
100		Gething et al., "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)			
101		Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)			
102		Goeddel et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)			
103		Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. coli" <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)			
104		Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)			
105		Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <u>Proc. Natl. Acad. Sci. USA</u> 79:6777-6781 (November 1982)			
106		Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" <u>Biochemistry</u> 19:2702-2710 (1980)			
107		Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)			
108		Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)			
109		Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells" <u>Nature</u> 295:503-508 (February 11, 1982)			
110		Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <u>Gene</u> 18:355-360 (1982)			
111		Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)			
112		Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)			
113		Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York: Pergamon Press Vol. 7:149-167 (1968)			
114		Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)			
115		Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)			
116		Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)			
117		Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V H gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 118 Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" Bio/Technology 6:1204-1210 (1988)
- 119 Hsiao et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" Proc. Natl. Acad. Sci. USA 76:3829-3833 (1979)
- 120 Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" Cell 84:299-308 (1996)
- 121 Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" Nature 194:495-496 (1962)
- 122 Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" Cell 66:233-243 (1991)
- 123 Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" Proc. Natl. Acad. Sci. USA 90:2551-2555 (March 1993)
- 124 Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" Nature 362:255-258 (March 18, 1993)
- 125 Johnson et al., "Expression and Structure of the Human NGF Receptor" Cell 47:545-554 (November 21, 1986)
- 126 Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" Nature 321:522-525 (May 29, 1986)
- 127 Jones, E., "Proteinase Mutants of *Saccharomyces Cerevisiae*" Genetics 85(1):23-33 (1977)
- 128 Keown et al., "Methods for Introducing DNA into Mammalian Cells" Methods in Enzymology 185:527-537 (1990)
- 129 Kingsman et al., "Replication in *Saccharomyces Cerevisiae* of Plasmid pBR313 Carrying DNA from the Yeast *trp1* Region" Gene 7:141-152 (1979)
- 130 Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" Nature 384:372-375 (1996)
- 131 Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" Nature 256:495-497 (August 7, 1975)
- 132 Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990)
- 133 Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" The Journal of Immunology 133(6):3001-3005 (1984)
- 134 Krammer et al., "Regulation of Apoptosis in the Immune System" Curr. Op. Immunol. 6:279-289 (1994)
- 135 Laimins et al., "Osmotic Control of kdp Operon Expression in *Escherichia Coli*" Proc. Natl. Acad. Sci. USA 78(1):464-468 (Jan 1981)
- 136 Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" J. Cell. Biochem. (abstract only, Supplement 15F; P432) p. 115 (1991)
- 137 Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" Proc. Natl. Acad. Sci. USA 88:2830-2834 (1991)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	138	Et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
	139	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (April 20, 1990)
	140	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)
	141	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular & Cellular Biology</u> 3(6):1108-1122 (June 1983)
	142	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
	143	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (Oct 10, 1997)
	144	Maeda et al., "Production of Human α -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)
	145	Mage et al., "Preparation of Fab and F(ab') ₂ Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 79-97 (1987)
	146	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	147	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
	148	Mantel et al., "Rabbit β -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
	149	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	150	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	151	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	152	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	153	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)
	154	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)
	155	Mather et al., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	156	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)
	157	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 158 Messing et al., "A System for Shotgun DNA Sequencing" Nucleic Acids Research 9(2):309-321 (1981)
- 159 Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" Genetic Engineering, Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)
- 160 Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" Nature 305:537-540 (1983)
- 161 Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" Cell 87(3):427-436 (1996)
- 162 Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" Proc. Natl. Acad. Sci. USA 81:6851-6855 (November 1984)
- 163 Morrison et al., "Transfer and expression of immunoglobulin genes" Annual Review of Immunology 2:239-256 (1984)
- 164 Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" Science 229:1202-1207 (September 20, 1985)
- 165 Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" Science 209:1422-1427 (Sep 1980)
- 166 Munro, "Uses of chimaeric antibodies" Nature 312:597 (1984)
- 167 Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" Analytical Biochemistry 107:220-239 (1980)
- 168 Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" Cell 85:817-827 (1996)
- 169 Nagata, "Apoptosis by Death Factor" Cell 88:355-365 (1997)
- 170 Nagata et al., "The Fas Death Factor" Science 267:1449-1456 (1995)
- 171 Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" Nature 312:604-608 (December 13, 1984)
- 172 Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" EMBO Journal 9:3269-3278 (1990)
- 173 Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" The Journal of Histochemistry and Cytochemistry 30(5):407-412 (1982)
- 174 Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" Molecular & Cellular Biology 4(7):1293-1305 (July 1984)
- 175 Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" Protein Eng. 3(6):547-553 (1990)
- 176 Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" Journal of Immunological Methods 40:219-230 (1981)
- 177 Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" Science 277:815-818 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

178	Han et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
179	Pavakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7398-7402 (December 1981)
180	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>Eur. J. Haematol.</u> 41:414-419 (1988)
181	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)
182	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
183	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
184	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
185	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (February 12, 1987)
186	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
187	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)
188	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)
189	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1beta Converting Enzyme" <u>Cell</u> 69:597-604 (1992)
190	Reyes et al., "Expression of Human β -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" <u>Nature</u> 297:598-601 (June 17, 1982)
191	Rice and Baltimore, "Regulated expression of an immunoglobulin κ gene introduced into a mouse lymphoid cell line" <u>Proc. Natl. Acad. Sci. USA</u> 79:7862-7865 (1982)
192	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (March 24, 1988)
193	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
*194	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
195	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (April 20, 1990)
196	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
197	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 198 Sharon et al., "Expression of a V_HC_K chimaeric protein in mouse myeloma cells" Nature 309:364-367 (1984)
- 199 Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" Gene 23:315-330 (1983)
- 200 Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" Science 277:818-821 (1997)
- 201 Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" Cell 20:269-281 (June 1980)
- 202 Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" Cell 89:309-319 (Apr 18, 1997)
- 203 Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" The Journal of Immunology 151(4):2296-2308 (Aug 1993)
- 204 Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" Journal of Biological Chemistry 266:14163-14166 (1991)
- 205 Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" Science 248:1019-1023 (May 25, 1990)
- 206 Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" Biochem. & Biophys. Res. Comm. 176:335-342 (1991)
- 207 Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" Cell 76:959-962 (1994)
- 208 Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" Archives of Biochemistry & Biophysics 259:52-57 (1987)
- 209 Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" J. Molec. Appl. Genet. 1:327-341 (1982)
- 210 Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" EMBO Journal 8(5):1403-1410 (1989)
- 211 Steller, "Mechanisms and Genes of Cellular Suicide" Science 267:1445-1449 (1995)
- 212 Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" Nature 282:39-43 (November 1, 1979)
- 213 Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" Molecular & Cellular Biology 5:410-413 (1985)
- 214 Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" Methods in Enzymology 121:210-228 (1986)
- 215 Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" Science 237(4817):893-896 (Aug. 1987)
- 216 Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" Immunogenetics 37:199-203 (1993)
- 217 Tartaglia et al., "A novel domain within the 55kd TNF receptor signals cell death" Cell 74(5):845-853 (1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 218 Tewari et al., "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" Journal of Biological Chemistry 270:3255-3260 (1995)
- 219 Tewari et al., "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" Curr. Op. Genet. Develop. 8:39-44 (1996)
- 220 Tewari et al., "Yama/CPP32beta, a Mammalian Homolog of CED-3, Is a CrmA-Inhibitible Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" Cell 81:801-809 (1995)
- 221 Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" Cell 51:503-512 (1987)
- 222 Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" Proc. Natl. Acad. Sci. USA 77(9):5201-5205 (September 1980)
- 223 Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" Science 267:1456-1462 (1995)
- 224 Thotakura et al., "Enzymatic Deglycosylation of Glycoproteins" Meth. Enzymol. 138:350-359 (1987)
- 225 Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" EMBO Journal 10(12):3655-3659 (1991)
- 226 Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" Nature 339:68-70 (1989)
- 227 Tschumper et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" Gene 10:157-166 (1980)
- 228 Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" Virology 184:370-382 (1991)
- 229 Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" Virology 160:20-29 (1987)
- 230 Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" Proc. Natl. Acad. Sci. USA 77(7):4216-4220 (July 1980)
- 231 Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" Bio/Technology 8:135-139 (1990)
- 232 Van Solingen et al., "Fusion of Yeast Spheroplasts" J. Bact. 130:946-947 (1977)
- 233 Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" Science 239:1534-1536 (Mar 25, 1988)
- 234 Verma et al., "Rel/NF-kB/IkB Family: Intimate Tales of Association and Dissociation" Genes Develop. 9:2723-2735 (1995)
- 235 von Bulow et al., "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" Science 278:138-141 (Oct 3, 1997)
- 236 Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" EMBO Journal 16(17):5386-5397 (1997)
- 237 Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" Nature 356:314-317 (1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1129

Serial No.

08/918,874

LIST OF DISCLOSURES CITED BY APPLICANT

Applicant

Ashkenazi et al.

Filing Date

26 Aug 1997

Group

1801

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 238 Weicher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" Proc. Natl. Acad. Sci. USA 88:159-163 (1991)
- 239 Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" Gene 34(2-3):315-323 (1985)
- 240 Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" Philos. Trans. R. Soc. London Ser A 317:415-423 (1986)
- 241 Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" Immunity 3:673-682 (1995)
- 242 Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" Journal of Biological Chemistry 272(40):25190-25194 (Oct 3, 1997)
- 243 Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" Journal of Biological Chemistry 266:12099-12104 (1991)
- 244 Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" Nature 297(6):17-18 (May 1982)
- 245 Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" Journal of Experimental Medicine 169:1747-1756 (1989)
- 246 Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" Nature 377:348-351 (1995)
- 247 Zola, "Using Monoclonal Antibodies: Soluble Antigens" Monoclonal Antibodies: A Manual of Techniques, CRC Press, Chapter 6, pps. 147-158 (1987)
- 248 Zoller et al., "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)
- 249 Zou et al., "Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c-Dependent Activation of Caspase-3" Cell 90:405-413 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.